Procedure For Body Fluid Antidepressant Test

1. Armbruster DA, Schwarzhoff RH, Pierce BL, and Hubster EC. Method comparison of EMIT II and ONLINE with RIA for drug screening. J Forensic Sci 1993; 38:1326-1341.

2. Armbruster DA, Schwarzhoff RH, Hubster EC, and Liserio MK. Enzyme immuno-assay, kinetic microparticle immunoassay, radioimmunoassay, and fluorescence polarization immunoassay compared for drugs-of-abuse screening. Clin Chem 1993;39:2137-2146.

3. Armbruster DA, Hubster EC, Kaufman MS, and Ramon MK. Cloned enzyme donor immunoassay (CEDIA) for drugs-of-abuse screening. Clin Chem 1995;41:92-98.

4. Beck O, Lin Z, Brodin K, Borg S, and Hjemdahl P. The Online screening technique for urinary benzodiazepines: comparison with EMIT, FPIA, and GC-MS. J Anal Toxicol 1997;21:554-557.

5. Baselt RC. Urine drug screening by immunoassay: interpretation of results, in Advances in Analytical Toxicology, Volume 1 (Baselt, RC, ed), Biomedical Publications, Foster City, CA: 1984; pp. 81-123.

6. Cone EJ, Presley L, Lehrer M, et al. Oral fluid testing for drugs of abuse: positive prevalence rates by Intercept immunoassay screening and GC-MS-MS confirmation and suggested cutoff concentrations. J Anal Toxicol 2002;26:541-546.

7. Ferrara SD, Tedeschi L, Frison G, et al. Drugs-of-abuse testing in urine: statistical approach and experimental comparison of immunochemical and chromatographic techniques. J Anal Toxicol 1994;18:278-291.

8. Gronholm M and Lillsunde P. A comparison between on-site immunoassay drug-testing devices and laboratory results. Forensic Sci Int 2001;121:37-46.

9. Hammett-Stabler CA, Pesce AJ, and Cannon DJ. Urine drug screening in the medical setting. Clin Chim Acta 2002;315:125-135.

10. Jenkins AJ and Goldberger BA. (eds). On-Site Drug Testing,. Humana Press, Totowa, NJ: 2002.

11. Kacinko SL, Barnes AJ, Kim I, et al. Performance characteristics of the Cozart RapiScan Oral Fluid Drug Testing System for opiates in comparison to ELISA and GC/MS following controlled codeine administration. Forensic Sci Int 2004; 141:41-48.

12. Kerrigan S and Phillips WH, Jr. Comparison of ELISAs for opiates, methamphet-amine, cocaine metabolite, benzodiazepines, phencyclidine, and cannabinoids in whole blood and urine. Clin Chem 2001;47:540-547.

13. Kroener L, Musshoff F, and Madea B. Evaluation of immunochemical drug screenings of whole blood samples. A retrospective optimization of cutoff levels after confirmation-analysis on GC-MS and HPLC-DAD. J Anal Toxicol 2003;27:205-212.

14. Moore KA, Werner C, Zannelli RM, Levine B, and Smith ML. Screening postmortem blood and tissues for nine classes [correction of cases] of drugs of abuse using automated microplate immunoassay. Forensic Sci Int 1999;106:93-102.

15. Smith ML, Hughes RO, Levine B, Dickerson S, Darwin WD, and Cone EJ. Forensic drug testing for opiates. VI. Urine testing for hydromorphone, hydrocodone, oxymorphone, and oxycodone with commercial opiate immunoassays and gas chromatography-mass spectrometry. J Anal Toxicol 1995;19:18-26.

16. Smith ML, Shimomura ET, Summers J, et al. Detection times and analytical performance of commercial urine opiate immunoassays following heroin administration. J Anal Toxicol 2000;24:522-529.

17. Walsh JM, Flegel R, Crouch DJ, Cangianelli L, and Baudys J. An evaluation of rapid point-of-collection oral fluid drug-testing devices. J Anal Toxicol 2003;27: 429-439.

18. Drummer OH. Chromatographic screening techniques in systematic toxicological analysis. J Chromatogr B Biomed Sci Appl 1999;733:27-45.

19. El Mahjoub A and Staub C. High-performance liquid chromatographic method for the determination of benzodiazepines in plasma or serum using the column-switching technique. J Chromatogr B Biomed Sci Appl 2000;742:381-390.

20. Maier RD and Bogusz M. Identification power of a standardized HPLC-DAD system for systematic toxicological analysis. J Anal Toxicol 1995;19:79-83.

21. Staub C. Chromatographic procedures for determination of cannabinoids in biological samples, with special attention to blood and alternative matrices like hair, saliva, sweat and meconium. J Chromatogr B Biomed Sci Appl 1999;733:119-126.

22. Tracqui A, Kintz P, and Mangin P. Systematic toxicological analysis using HPLC/DAD. J Forensic Sci 1995;40:254-262.

23. Valli A, Polettini A, Papa P, and Montagna M. Comprehensive drug screening by integrated use of gas chromatography/mass spectrometry and Remedi HS. Ther Drug Monit 2001;23:287-294.

24. Dawling S and Widdop B. Use and abuse of the Toxi-Lab TLC system. Ann Clin Biochem 1988;25:708-709.

25. Jain R. Utility of thin layer chromatography for detection of opioids and benzodi-azepines in a clinical setting. Addict Behav 2000;25:451-454.

26. Jarvie DR and Simpson D. Drug screening: evaluation of the Toxi-Lab TLC system. Ann Clin Biochem 1986;23 (Pt 1):76-84.

27. Lillsunde P and Korte T. Comprehensive drug screening in urine using solid-phase extraction and combined TLC and GC/MS identification. J Anal Toxicol 1991;15: 71-81.

28. Otsubo K, Seto H, Futagami K, and Oishi R. Rapid and sensitive detection of benzodiazepines and zopiclone in serum using high-performance thin-layer chroma-tography. J Chromatogr B Biomed Appl 1995;669:408-412.

29. Lemos NP, Bortolotti F, Manetto G, Anderson, RA, Cittadini F, and Tagliaro F. Capillary electrophoresis: a new tool in forensic medicine and science. Sci Justice 2001;41:203-210.

30. Manetto G, Crivellente F, and Tagliaro F. Capillary electrophoresis: a new analytical tool for forensic toxicologists. Ther Drug Monit 2000;22:84-88.

31. Kapnissi CP and Warner IM. Separation of benzodiazepines using capillary elec-trochromatography. J Chromatogr Sci 2004;42:238-244.

32. Tagliaro F, Turrina S, Pisi P, Smith FP, and Marigo M. Determination of illicit and/or abused drugs and compounds of forensic interest in biosamples by capillary electrophoretic/electrokinetic methods. J Chromatogr B Biomed Sci Appl 1998; 713:27-49.

33. Thormann W. Progress of capillary electrophoresis in therapeutic drug monitoring and clinical and forensic toxicology. Ther Drug Monit 2002;24:222-231.

34. Wernly P and Thormann W. Analysis of illicit drugs in human urine by micellar electrokinetic capillary chromatography with on-column fast scanning polychrome absorption detection. Anal Chem 1991;63:2878-2882.

35. Bogusz MJ, Maier RD, Kruger KD, and Kohls U. Determination of common drugs of abuse in body fluids using one isolation procedure and liquid chromatography— atmospheric-pressure chemical-ionization mass spectromery. J Anal Toxicol 1998; 22:549-558.

36. Bogusz MJ. Hyphenated liquid chromatographic techniques in forensic toxicology. J Chromatogr B Biomed Sci Appl 1999;733:65-91.

37. Bogusz MJ. Liquid chromatography-mass spectrometry as a routine method in forensic sciences: a proof of maturity. J Chromatogr B Biomed Sci Appl 2000;748: 3-19.

38. Breindahl T and Andreasen K. Validation of urine drug-of-abuse testing methods for ketobemidone using thin-layer chromatography and liquid chromatography-electrospray mass spectrometry. J Chromatogr B Biomed Sci Appl 1999;736: 103-113.

39. Dams R, Murphy CM, Lambert WE, and Huestis MA. Urine drug testing for opi-oids, cocaine, and metabolites by direct injection liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2003;17:1665-1670.

40. Dams R, Murphy CM, Choo RE, Lambert WE, De Leenheer AP, and Huestis MA. LC-atmospheric pressure chemical ionization-MS/MS analysis of multiple illicit drugs, methadone, and their metabolites in oral fluid following protein precipitation. Anal Chem 2003;75:798-804.

41. Goldberger BA and Cone EJ. Confirmatory tests for drugs in the workplace by gas chromatography-mass spectrometry. J Chromatogr A 1994;674:73-86.

42. Hoja H, Marquet P, Verneuil B, Lotfi H, Penicaut B, and Lachatre G. Applications of liquid chromatography-mass spectrometry in analytical toxicology: a review. J Anal Toxicol 1997;21:116-126.

43. Kintz P and Cirimele V. Testing human blood for cannabis by GC-MS. Biomed Chromatogr 1997;11:371-373.

44. Lehrer M. The role of gas chromatography/mass spectrometry. Instrumental techniques in forensic urine drug testing. Clin Lab Med 1998;18:631-649.

45. Marquet P. Progress of liquid chromatography-mass spectrometry in clinical and forensic toxicology. Ther Drug Monit 2002;24:255-276.

46. Maurer HH. Liquid chromatography-mass spectrometry in forensic and clinical toxicology. J Chromatogr B Biomed Sci Appl 1998;713:3-25.

47. Maurer HH. Systematic toxicological analysis procedures for acidic drugs and/or metabolites relevant to clinical and forensic toxicology and/or doping control. J Chromatogr B Biomed Sci Appl 1999;733:3-25.

48. Maurer HH. Role of gas chromatography-mass spectrometry with negative ion chemical ionization in clinical and forensic toxicology, doping control, and biomonitoring. Ther Drug Monit 2002;24:247-254.

49. Maurer HH, Kraemer, T, Kratzsch, C, Peters, FT, and Weber, AA. Negative ion chemical ionization gas chromatography-mass spectrometry and atmospheric pressure chemical ionization liquid chromatography-mass spectrometry of low-dosed and/or polar drugs in plasma. Ther Drug Monit 2002;24:117-124.

50. Moeller MR, Steinmeyer S, and Kraemer T. Determination of drugs of abuse in blood. J Chromatogr B Biomed Sci Appl 1998;713:91-109.

51. Moeller MR and Kraemer T. Drugs of abuse monitoring in blood for control of driving under the influence of drugs. Ther Drug Monit 2002;24:210-221.

52. Nordgren HK and Beck O. Multicomponent screening for drugs of abuse: direct analysis of urine by LC-MS-MS. Ther Drug Monit 2004;26:90-97.

53. Peat MA. Advances in forensic toxicology. Clin Lab. Med 1998;18:263-278.

54. Peters FT, Kraemer T, and Maurer HH. Drug testing in blood: validated negativeion chemical ionization gas chromatographic-mass spectrometric assay for determination of amphetamine and methamphetamine enantiomers and its application to toxicology cases. Clin Chem 2002;48:1472-1485.

55. Polettini A, Groppi A, Vignali C, and Montagna M. Fully-automated systematic toxicological analysis of drugs, poisons, and metabolites in whole blood, urine, and plasma by gas chromatography-full scan mass spectrometry. J Chromatogr B Biomed Sci Appl 1998;713:265-279.

56. Polettini A. Systematic toxicological analysis of drugs and poisons in biosamples by hyphenated chromatographic and spectroscopic techniques. J Chromatogr B Biomed Sci Appl 1999;733:47-63.

57. Saint-Marcoux F, Lachatre G, and Marquet P. Evaluation of an improved general unknown screening procedure using liquid chromatography-electrospray-mass spectrometry by comparison with gas chromatography and high-performance liquid-chromatography-diode array detection. J Am Soc Mass Spectrom 2003; 14: 14-22.

58. Solans A, Carnicero M, de la Torre R, and Segura J. Comprehensive screening procedure for detection of stimulants, narcotics, adrenergic drugs, and their metabolites in human urine. J Anal Toxicol 1995;19:104-114.

59. Song SM, Marriott P, Kotsos A, Drummer OH, and Wynne P. Comprehensive two-dimensional gas chromatography with time-of-flight mass spectrometry (GC x GC-TOFMS) for drug screening and confirmation. Forensic Sci Int 2004;143:87-101.

60. Venisse N, Marquet P, Duchoslav E, Dupuy JL, and Lachatre G. A general unknown screening procedure for drugs and toxic compounds in serum using liquid chromatography-electrospray-single quadrupole mass spectrometry. J Anal Toxicol 2003;27:7-14.

61. Weinmann W, Vogt S, Goerke R, Muller C, and Bromberger, A. Simultaneous determination of THC-COOH and THC-COOH-glucuronide in urine samples by LC/MS/MS. Forensic Sci Int 2000;113:381-387.

62. Yonamine M, Tawil N, Moreau RL, and Silva OA. Solid-phase micro-extraction-gas chromatography-mass spectrometry and headspace-gas chromatography of tetrahy-drocannabinol, amphetamine, methamphetamine, cocaine and ethanol in saliva samples. J Chromatogr B Analyt Technol Biomed Life Sci 2003;789:73-78.

63. Barcelo-Barrachina E, Moyano E, and Galceran MT. State-of-the-art of the hyphenation of capillary electrochromatography with mass spectrometry. Electrophoresis 2004;25:1927-1948.

64. Lazar IM, Naisbitt G, and Lee ML. Capillary electrophoresis-time-of-flight mass spectrometry of drugs of abuse. Analyst 1998;123:1449-1454.

65. Kosnoski EM, Yolton RL, Citek K, Hayes CE, and Evans RB. The Drug Evaluation Classification Program: using ocular and other signs to detect drug intoxication. J Am Optom Assoc 1998;69:211-227.

66. Heishman SJ, Singleton EG, and Crouch DJ. Laboratory validation study of drug evaluation and classification program: ethanol, cocaine, and marijuana. J Anal Toxicol 1996;20:468-483.

67. Heishman SJ, Singleton EG, and Crouch DJ. Laboratory validation study of drug evaluation and classification program: alprazolam, d-amphetamine, codeine, and marijuana. J Anal Toxicol 1998;22:503-514.

68. Mandatory guidelines for federal workplace drug testing programs. Fed Regist 59, 29908 (http://www.health.org/workplace/GDLNS-94.htm) or (http://workplace. samhsa.gov/fedprograms/MandatoryGuidelines/HHS09011994.pdf), 1994.

69. Proposed Revisions to Mandatory Guidelines for Federal Workplace Drug Testing Programs. Fed Regist 2004;69:19,673-19,732; http://a257.g.akamaitech.net/ 7/257/2422/14mar20010800/edocket.access.gpo.gov/2004/pdf/04-7984.pdf.

70. Braithwaite RA, Jarvie DR, Minty PS, Simpson D, and Widdop B. Screening for drugs of abuse. I: Opiates, amphetamines and cocaine. Ann Clin Biochem 1995;32 (Pt 2):123-153.

71. Simpson D, Braithwaite RA, Jarvie DR, et al. Screening for drugs of abuse (II): cannabinoids, lysergic acid diethylamide, buprenorphine, methadone, barbiturates, benzodiazepines and other drugs. Ann Clin Biochem 1997;34:460-510.

72. Chang TL, Chen KW, Lee YD, and Fan K. Determination of benzodiazepines in clinical serum samples: comparative evaluation of REMEDi system, aca analyzer, and conventional HPLC performance. J Clin Lab Anal 1999;13:106-111.

73. Drummer OH. Methods for the measurement of benzodiazepines in biological samples. J Chromatogr B Biomed Sci Appl 1998;713:201-225.

74. Schwenzer KS, Pearlman R, Tsilimidos M, et al. New fluorescence polarization immunoassays for analysis of barbiturates and benzodiazepines in serum and urine: performance characteristics. J Anal Toxicol 2000;24:726-732.

75. Burnley BT and George S. The development and application of a gas chromato-graphy-mass spectrometric (GC-MS) assay to determine the presence of 2-oxo-3-hydroxy-LSD in urine. J Anal Toxicol 2003;27:249-252.

76. Cody JT and Valtier S. Immunoassay analysis of lysergic acid diethylamide. J Anal Toxicol 1997;21:459-464.

77. Hoja H, Marquet P, Verneuil B, Lotfi H, Dupuy JL, and Lachatre G. Determination of LSD and N-demethyl-LSD in urine by liquid chromatography coupled to elec-trospray ionization mass spectrometry. J Chromatogr B Biomed Sci Appl 1997; 692:329-335.

78. Schneider S, Kuffer P, and Wennig R. Determination of lysergide (LSD) and phen-cyclidine in biosamples. J Chromatogr B Biomed Sci Appl 1998;713:189-200.

78a. Plaut O, Girod C, and Staub C. Analysis of methaqualone in biological matrices by micellar electrokinetic capillary chromatography. Comparison with gas chromatography-mass spectrometry. Forensic Sci Int 1998;92:219-227.

79. Frost M, Kohler H, and Blaschke G. Enantioselective determination of methadone and its main metabolite 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) in serum, urine and hair by capillary electrophoresis. Electrophoresis 1997;18: 1026-1034.

80. Lakso HA and Norstrom A. Determination of dextropropoxyphene and nordex-tropropoxyphene in urine by liquid chromatography-electrospray ionization mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2003;794: 57-65.

81. McNally AJ, Pilcher I, Wu R, et al. Evaluation of the OnLine immunoassay for propoxyphene: comparison to EMIT II and GC-MS. J Anal Toxicol 1996;20: 537-540.

82. Hendrickson RG and Morocco AP. Quetiapine cross-reactivity among three tricyclic antidepressant immunoassays. J Toxicol. Clin Toxicol 2003;41:105-108.

83. Schwartz JG, Hurd IL, and Carnahan JJ. Determination of tricyclic antidepressants for ED analysis. Am J Emerg Med 1994;12:513-516.

84. de Boer D and Bosman I. A new trend in drugs-of-abuse; the 2C-series of phenethylamine designer drugs. Pharm World Sci 2004;26:110-113.

85. Ensslin HK, Kovar KA, and Maurer HH. Toxicological detection of the designer drug 3,4-methylenedioxyethylamphetamine (MDE, "Eve") and its metabolites in urine by gas chromatography-mass spectrometry and fluorescence polarization immunoassay. J Chromatogr B Biomed Appl 1996;683:189-197.

86. Kraemer T and Maurer HH. Determination of amphetamine, methamphetamine and amphetamine-derived designer drugs or medicaments in blood and urine. J Chromatogr B Biomed Sci Appl 1998;713:163-187.

87. Marquet P, Lacassie E, Battu C, Faubert H, and Lachatre G. Simultaneous determination of amphetamine and its analogs in human whole blood by gas chromatography-mass spectrometry. J Chromatogr B Biomed Sci Appl 1997;700: 77-82.

88. Maurer HH, Bickeboeller-Friedrich J, Kraemer T, and Peters FT. Toxicokinetics and analytical toxicology of amphetamine-derived designer drugs ('Ecstasy'). Toxicol Lett 2000;112-113:133-142.

89. Moeller MR and Hartung M. Ecstasy and related substances—serum levels in impaired drivers. J Anal Toxicol 1997;21:591.

90. Nordgren HK and Beck O. Direct screening of urine for MDMA and MDA by liquid chromatography-tandem mass spectrometry. J Anal Toxicol 2003;27:15-19.

91. Pizarro N, Ortuno J, Farre M, et al. Determination of MDMA and its metabolites in blood and urine by gas chromatography-mass spectrometry and analysis of enantiomers by capillary electrophoresis. J Anal Toxicol 2002;26:157-165.

92. Ramseier A, Caslavska J, and Thormann W. Stereoselective screening for and confirmation of urinary enantiomers of amphetamine, methamphetamine, designer drugs, methadone and selected metabolites by capillary electrophoresis. Electrophoresis 1999;20:2726-2738.

93. Crouch DJ, Rollins DE, Canfield DV, Andrenyak DM, and Schulties JE. Quanti-tation of alprazolam and alpha-hydroxyalprazolam in human plasma using liquid chromatography electrospray ionization MS-MS. J Anal Toxicol 1999;23: 479-485.

94. Bogusz MJ, Maier RD, Kruger KD, and Fruchtnicht W. Determination of flunitra-zepam and its metabolites in blood by high-performance liquid chromatography-atmospheric pressure chemical ionization mass spectrometry. J Chromatogr B Biomed Sci Appl 1998;713:361-369.

95. ElSohly MA, Feng S, Salamone SJ, and Brenneisen R. GC-MS determination of flunitrazepam and its major metabolite in whole blood and plasma. J Anal Toxi-col 1999;23:486-489.

96. ElSohly MA, Feng S, Salamone SJ, and Wu R. A sensitive GC-MS procedure for the analysis of flunitrazepam and its metabolites in urine. J Anal Toxicol 1997; 21:335-340.

97. Moeller MR and Mueller C. The detection of 6-monoacetylmorphine in urine, serum and hair by GC/MS and RIA. Forensic Sci Int 1995;70:125-133.

98. Presley L, Lehrer M, Seiter W, et al. High prevalence of 6-acetylmorphine in morphine-positive oral fluid specimens. Forensic Sci Int 2003;133:22-25.

99. Spanbauer AC, Casseday S, Davoudzadeh D, Preston KL, and Huestis MA. Detection of opiate use in a methadone maintenance treatment population with the CEDIA 6-acetylmorphine and CEDIA DAU opiate assays. J Anal Toxicol 2001;25:515-519.

100. Cirimele V, Kintz P, Lohner S, and Ludes B. Enzyme immunoassay validation for the detection of buprenorphine in urine. J Anal Toxicol 2003;27:103-105.

101. Hoja H, Marquet P, Verneuil B, Lotfi H, Dupuy JL, and Lachatre G. Determination of buprenorphine and norbuprenorphine in whole blood by liquid chromatography-mass spectrometry. J Anal Toxicol 1997;21:160-165.

102. Polettini A and Huestis MA. Simultaneous determination of buprenor-phine, norbuprenorphine, and buprenorphine-glucuronide in plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Biomed Sci Appl 2001;754:447-459.

103. Caplan YH and Goldberger BA. Alternative specimens for workplace drug testing. J Anal Toxicol 2001;25:396-399.

104. ElSohly MA and Feng S. Delta 9-THC metabolites in meconium: identification of 11-OH-delta 9-THC, 8 beta,11-diOH-delta 9-THC, and 11-nor-delta 9-THC-9-COOH as major metabolites of delta 9-THC. J Anal Toxicol 1998;22:329-335.

105. ElSohly MA, Stanford DF, Murphy TP, et al. Immunoassay and GC-MS procedures for the analysis of drugs of abuse in meconium. J Anal Toxicol 1999;23: 436-445.

106. Feng S, ElSohly MA, Salamone S, and Salem MY. Simultaneous analysis of delta9-THC and its major metabolites in urine, plasma, and meconium by GC-MS using an immunoaffinity extraction procedure. J Anal Toxicol 2000; 24:395-402.

107. Huestis MA, Oyler JM, Cone EJ, Wstadik AT, Schoendorfer D, and Joseph RE, Jr. Sweat testing for cocaine, codeine and metabolites by gas chromatography-mass spectrometry. J Chromatogr B Biomed Sci Appl 1999;733:247-264.

108. Huestis MA, Cone EJ, Wong CJ, Umbricht A, and Preston KL. Monitoring opiate use in substance abuse treatment patients with sweat and urine drug testing. J Anal Toxicol 2000;24:509-521.

109. Jenkins AJ, Oyler JM, and Cone EJ. Comparison of heroin and cocaine concentrations in saliva with concentrations in blood and plasma. J Anal Toxicol 1995; 19:359-374.

110. Kato K, Hillsgrove M, Weinhold L, Gorelick DA, Darwin WD, and Cone EJ. Cocaine and metabolite excretion in saliva under stimulated and nonstimulated conditions. J Anal Toxicol 1993;17:338-341.

111. Kidwell DA, Holland JC, and Athanaselis S. Testing for drugs of abuse in saliva and sweat. J Chromatogr B Biomed Sci Appl 1998;713:111-135.

112. Kidwell DA and Smith FP. Susceptibility of PharmChek drugs of abuse patch to environmental contamination. Forensic Sci Int 2001;116:89-106.

113. Kidwell DA, Kidwell JD, Shinohara F, et al. Comparison of daily urine, sweat, and skin swabs among cocaine users. Forensic Sci Int 2003;133:63-78.

114. Kintz P and Samyn N. Use of alternative specimens: drugs of abuse in saliva and doping agents in hair. Ther Drug Monit 2002;24:239-246.

115. Moore C, Negrusz A, and Lewis D. Determination of drugs of abuse in meco-nium. J Chromatogr B Biomed Sci Appl 1998;713:137-146.

116. Niedbala RS, Kardos KW, Fritch DF, et al. Detection of marijuana use by oral fluid and urine analysis following single-dose administration of smoked and oral marijuana. J Anal Toxicol 2001;25:289-303.

117. Ostrea EM, Jr. Testing for exposure to illicit drugs and other agents in the neonate: a review of laboratory methods and the role of meconium analysis. Curr Probl Pediatr 1999;29:37-56.

118. Buchan BJ, Walsh JM, and Leaverton PE. Evaluation of the accuracy of on-site multi-analyte drug testing devices in the determination of the prevalence of illicit drugs in drivers, J Forensic Sci 1998;43:395-399.

119. Department of Transportation, National Highway Traffic Safety Administration (NHTSA). Field test of on-site drug detection devices, DOT HS 809 192 (http:// www.nhtsa.dot.gov/people/injury/research/pub/onsitedetection/Drug_index.htm), 2000.

120. Jehanli A, Brannan S, Moore L, and Spiehler VR. Blind trials of an onsite saliva drug test for marijuana and opiates. J Forensic Sci 2001;46:1214-1220.

121. Roadside Testing Assessment (ROSITA). Work package 2, Deliverable D2, Inventory of state-of-the-art road side drug testing equipment. (www.rosita.org), 1999.

122. Walsh JM. On-site testing devices and driving-under-the-influence cases, in On-Site Drug Testing (Jenkins AJ and Goldberger BA, eds), Humana Press, Totowa, NJ: 2002; pp. 67-76.

European Workplace Drug Testing Society (EWDTS). European Laboratory Guidelines for Legally Defensible Workplace Drug Testing. (http://www.ewdts. org/guidelines.html), 2002.

Brendler J and Liu RH. Initial test cutoff selection based on regression analysis of initial test apparent analyte result vs GC/MS test analyte result—evaluation of two radioimmunoassay kits' test data. Clin Chem 1997;43:688-690. Cone EJ, Sampson-Cone AH, Darwin WD, Huestis MA, and Oyler JM. Urine testing for cocaine abuse: metabolic and excretion patterns following different routes of administration and methods for detection of false-negative results. J Anal Toxicol 2003;27:386-401.

Huestis MA, Mitchell JM, and Cone EJ. Lowering the federally mandated cannabinoid immunoassay cutoff increases true-positive results. Clin Chem 1994; 40:729-733.

Liu RH, Edwards C, Baugh LD, Weng JL, Fyfe MJ, and Walia AS. Selection of an appropriate initial test cutoff concentration for workplace drug urinalysis— Cannabis example. J Anal Toxicol 1994;18:65-70.

Luzzi VI, Saunders AN, Koenig JW, et al. Analytic performance of immuno-assays for drugs of abuse below established cutoff values. Clin Chem 2004;50: 717-722.

Smith-Kielland A, Skuterud B, and Morland J. Urinary excretion of 11-nor-9-carboxy-delta9-tetrahydrocannabinol and cannabinoids in frequent and infrequent drug users. J Anal Toxicol 1999;23:323-332.

Vandevenne M, Vandenbussche H, and Verstraete A. Detection time of drugs of abuse in urine. Acta Clin Belg 2000;55:323-333.

Wingert WE. Lowering cutoffs for initial and confirmation testing for cocaine and marijuana: large-scale study of effects on the rates of drug-positive results. Clin Chem 1997;43:100-103.

Ensing K, Bosman IJ, Egberts AC, Franke JP, and de Zeeuw RA. Application of radioreceptor assays for systematic toxicological analysis—2. Theoretical considerations and evaluation. J Pharm Biomed Anal 1994;12:59-63. Janssen MJ, Ensing K, and de Zeeuw RA. Improved benzodiazepine radioreceptor assay using the MultiScreen Assay System. J Pharm Biomed Anal 1999;20: 753-761.

Janssen MJ, Ensing K, and de Zeeuw RA. Fluorescent-labeled ligands for the benzodiazepine receptor. Part 2: The choice of an optimal fluorescent-labeled ligand for benzodiazepine receptor assays. Pharmazie 2000;55:102-106. Nishikawa T, Ohtani H, Herold DA, and Fitzgerald RL. Comparison of assay methods for benzodiazepines in urine. A receptor assay, two immunoassays, and gas chromatography-mass spectrometry. Am J Clin Pathol 1997; 107: 345-352.

Joseph R, Dickerson S, Willis R, Frankenfield D, Cone EJ, and Smith DR. Interference by nonsteroidal anti-inflammatory drugs in EMIT and TDx assays for drugs of abuse. J Anal Toxicol 1995;19:13-17.

Colbert DL. Drug abuse screening with immunoassays: unexpected cross-reactivities and other pitfalls. Br J Biomed Sci 1994;51:136-146.

138. Ward C, McNally AJ, Rusyniak D, and Salamone SJ. 125I radioimmunoassay for the dual detection of amphetamine and methamphetamine. J Forensic Sci 1994; 39:1486-1496.

139. Hino Y, Ojanpera I, Rasanen I, and Vuori E. Performance of immunoassays in screening for opiates, cannabinoids and amphetamines in post-mortem blood. Forensic Sci Int 2003;131:148-155.

140. Asselin WM and Leslie JM. Use of the EMITtox serum tricyclic antidepressant assay for the analysis of urine samples. J Anal Toxicol 1990;14:168-171.

141. Bogusz M, Aderjan R, Schmitt G, Nadler E, and Neureither B. The determination of drugs of abuse in whole blood by means of FPIA and EMIT-dau immunoassays—a comparative study. Forensic Sci Int 1990;48:27-37.

142. Gjerde H, Christophersen AS, Skuterud B, Klemetsen K, and Morland J. Screening for drugs in forensic blood samples using EMIT urine assays. Forensic Sci Int 1990;44:179-185.

143. Maier RD, Erkens M, Hoenen H, and Bogusz M. The screening for common drugs of abuse in whole blood by means of EMIT-ETS and FPIA-ADx urine immunoassays. Int J Legal Med 1992;105:115-119.

144. Chronister CW, Walrath JC, and Goldberger BA. Rapid detection of benzoylec-gonine in vitreous humor by enzyme immunoassay. J Anal Toxicol 2001;25: 621-624.

145. Iwersen-Bergmann S, and Schmoldt A. Direct semiquantitative screening of drugs of abuse in serum and whole blood by means of CEDIA DAU urine immuno-assays. J Anal Toxicol 1999;23:247-256.

146. Loor R, Lingenfelter C, Wason PP, Tang K, and Davoudzadeh D. Multiplex assay of amphetamine, methamphetamine, and ecstasy drug using CEDIA technology. J Anal Toxicol 2002;26:267-273.

147. Way BA, Walton KG, Koenig JW, Eveland BJ, and Scott MG. Comparison between the CEDIA and EMIT II immunoassays for the determination of benzo-diazepines. Clin Chim Acta 1998;271:1-9.

148. Fraser AD, and Worth D. Monitoring urinary excretion of cannabinoids by fluorescence-polarization immunoassay: a cannabinoid-to-creatinine ratio study. Ther Drug Monit 2002;24:746-750.

149. Baker DP, Murphy MS, Shepp PF, et al. Evaluation of the Abuscreen ONLINE assay for amphetamines on the Hitachi 737: comparison with EMIT and GC/MS methods. J Forensic Sci 1995;40:108-112.

150. Boettcher M, Haenseler E, Hoke C, Nichols J, Raab D, and Domke I. Precision and comparability of Abuscreen OnLine assays for drugs of abuse screening in urine on Hitachi 917 with other immunochemical tests and with GC/MS. Clin Lab 2000;46:49-52.

151. Moody DE and Medina AM. OnLine kinetic microparticle immunoassay of cannabinoids, morphine, and benzoylecgonine in serum. Clin Chem 1995;41:1664-1665.

152. Smith FP, Lora-Tamayo C, Carvajal R, Caddy B, and Tagliaro F. Assessment of an automated immunoassay based on kinetic interaction of microparticles in solution for determination of opiates and cocaine metabolite in urine. Ann Clin Biochem 1997;34 (Pt 1), 81-84.

Klotz U. Performance of a new automated substrate-labeled fluorescence immunoassay system evaluated by comparative therapeutic monitoring of five drugs. Ther Drug Monit 1984;6:355-359.

Sheehan M and Caron G. Evaluation of an automated system (Optimate) for substrate-labeled fluorescent immunoassays. Ther Drug Monit 1985;7:108-114. Sharma JD, Aherne GW, and Marks V. Enhanced chemiluminescent enzyme immunoassay for cannabinoids in urine. Analyst 1989;114:1279-1282. Caslavska J, Allemann D, and Thormann W. Analysis of urinary drugs of abuse by a multianalyte capillary electrophoretic immunoassay. J Chromatogr A 1999; 838:197-211.

Nath N, Eldefrawi M, Wright J, Darwin D, and Huestis M. A rapid reusable fiber optic biosensor for detecting cocaine metabolites in urine. J Anal Toxicol 1999; 23:460-467.

Tsai JSC, Deng D, Diebold E, Smith A, Wentzel C, and Franzke S. The latest development in biosensor immunoassay technology for drug assays. LABOLife, 2002;Nr.4/02:17-20.

Yu H, Kusterbeck AW, Hale MJ, Ligler FS, and Whelan JP. Use of the USDT flow immunosensor for quantitation of benzoylecgonine in urine. Biosens Bio-electron 1996;11:725-734.

Armbruster DA and Krolak JM. Screening for drugs of abuse with the Roche ONTRAK assays. J Anal Toxicol 1992;16:172-175.

Beck O, Kraft M, Moeller MR, Smith BL, Schneider S, and Wennig R. Frontline immunochromatographic device for on-site urine testing of amphetamines: laboratory validation using authentic specimens. Ann Clin Biochem 2000;37(Pt 2), 199-204.

Klimov AD, Tsai S-CJ, Towt J, Salamone SJ. Improved immuno-chromatographic format for competitive-type assays. Clin Chem 1995;41:1360. Leino A, Saarimies J, Gronholm M, and Lillsunde P. Comparison of eight commercial on-site screening devices for drugs-of-abuse testing, Scand J Clin Lab Invest 2001;61:325.

Peace MR, Poklis JL, Tarnai LD, and Poklis A. An evaluation of the OnTrak

Testcup-er on-site urine drug-testing device for drugs commonly encountered from emergency departments. J Anal Toxicol 2002;26:500-503.

Towt J, Tsai SC, Hernandez MR, et al. ONTRAK TESTCUP: a novel, on-site, multi-analyte screen for the detection of abused drugs. J Anal Toxicol 1995; 19:

504-510.

Yang JM and Lewandrowski KB. Urine drugs of abuse testing at the point-of-care: clinical interpretation and programmatic considerations with specific reference to the Syva Rapid Test (SRT). Clin Chim Acta 2001;307:27-32. Weiss A. Concurrent Engineering for Lateral-Flow Diagnostics, IVD Technology 1999;5:48-57.

Buechler KF, Moi S, Noar B, et al. Simultaneous detection of seven drugs of abuse by the Triage panel for drugs of abuse, Clin Chem 1992;38:1678-1684. International Union of Pure and Applied Chemistry, http://www.iupac.org/ publications/analytical_compendium/

170. Jain R. Utility of thin layer chromatography for detection of opioids and benzo-diazepines in a clinical setting. Addict Behav 2000;25:451-454.

171. Lillsunde P and Korte T. Comprehensive drug screening in urine using solidphase extraction and combined TLC and GC/MS identification. J Anal Toxicol 1991;15:71-81.

172. Steinberg DM, Sokoll LJ, Bowles KC, et al. Clinical evaluation of Toxi.Prep: a semiautomated solid-phase extraction system for screening of drugs in urine. Clin Chem 1997;43:2099-2105.

173. Gioino G, Hansen C, Pacchioni A, et al. Use of high-performance liquid chro-matography with diode-array detection after a primary drug screening in patients admitted to the emergency department. Ther Drug Monit 2003;25:99-106.

174. Otsubo K, Seto H, Futagami K, and Oishi R. Rapid and sensitive detection of benzodiazepines and zopiclone in serum using high-performance thin-layer chromatography. J Chromatogr B Biomed Appl 1995;669:408-412.

175. Simonovska B, Prosek M, Vovk I, and Jelen-Zmitek A. High-performance thin-layer chromatographic separation of ranitidine hydrochloride and two related compounds. J Chromatogr B Biomed Sci Appl 1998;715:425-430.

176. Hackett LP, Dusci LJ, Ilett KF, and Chiswell GM. Optimizing the hydrolysis of codeine and morphine glucuronides in urine. Ther Drug Monit 2002;24:652-657.

177. Kemp PM, Abukhalaf IK, Manno JE, et al. Cannabinoids in humans. II. The influence of three methods of hydrolysis on the concentration of THC and two metabolites in urine. J Anal Toxicol 1995;19:292-298.

178. Skopp G and Potsch L. An investigation of the stability of free and glucu-ronidated 11-nor-delta9-tetrahydrocannabinol-9-carboxylic acid in authentic urine samples. J Anal Toxicol 2004;28:35-40

179. Bogusz MJ, Maier RD, Schiwy-Bochat KH, and Kohls U. Applicability of various brands of mixed-phase extraction columns for opiate extraction from blood and serum. J Chromatogr B Biomed Appl 1996;683:177-188.

180. Brown H, Kirkbride KP, Pigou PE, and Walker GS. New developments in SPME, Part 1: The use of vapor-phase deprotonation and on-fiber derivatization with alkylchloroformates in the analysis of preparations containing amphetamines. J Forensic Sci 2003;48:1231-1238.

181. Chiarotti M. Overview on extraction procedures. IntForensic Sci Int 1993;63: 161-170.

182. Garside D, Goldberger BA, Preston KL, and Cone EJ. Rapid liquid-liquid extraction of cocaine from urine for gas chromatographic-mass spectrometric analysis. J Chromatogr B Biomed Sci Appl 1997; 692:61-65.

183. Gerlits J. GC/MS quantitation of benzoylecgonine following liquid-liquid extraction of urine. J Forensic Sci 1993;38:1210-1214.

184. Soriano T, Jurado C, Menendez M, and Repetto M. Improved solid-phase extraction method for systematic toxicological analysis in biological fluids. J Anal Tox-icol 2001;25:137-143.

185. Yonamine M, Tawil N, Moreau RL, and Silva OA. Solid-phase micro-extraction-gas chromatography-mass spectrometry and headspace-gas chroma-tography of tetrahydrocannabinol, amphetamine, methamphetamine, cocaine and ethanol in saliva samples. J Chromatogr B Analyt Technol Biomed Life Sci 2003;789:73-78.

Lisi AM, Kazlauskas R, and Trout GJ. Gas chromatographic-mass spectrometric quantitation of urinary 11-nor-delta 9-tetrahydrocannabinol-9-carboxylic acid after derivatization by direct extractive alkylation. J Chromatogr 1993;617: 265-270.

Lisi AM, Kazlauskas R, and Trout GJ. Gas chromatographic-mass spectrometric quantitation of urinary buprenorphine and norbuprenorphine after derivatization by direct extractive alkylation. J Chromatogr B Biomed Sci Appl 1997;692:67-77. Maurer HH, Tauvel FX, and Kraemer T. Screening procedure for detection of non-steroidal anti-inflammatory drugs and their metabolites in urine as part of a systematic toxicological analysis procedure for acidic drugs and poisons by gas chromatography-mass spectrometry after extractive methylation. J Anal Toxicol 2001;25:237-244

Cremese M, Wu AH, Cassella G, O'Connor E, Rymut K, and Hill DW. Improved GC/MS analysis of opiates with use of oxime-TMS derivatives. J Forensic Sci 1998;43:1220-1224.

Melgar R and Kelly RC. A novel GC/MS derivatization method for amphetamines. J Anal Toxicol 1993;17:399-402.

Segura J, Ventura R, and Jurado C. Derivatization procedures for gas chromato-graphic-mass spectrometric determination of xenobiotics in biological samples, with special attention to drugs of abuse and doping agents. J Chromatogr B Biomed Sci Appl 1998;713:61-90.

Liu RH, Foster G, Cone EJ, and Kumar SD. Selecting an appropriate isotopic internal standard for gas chromatography/mass spectrometry analysis of drugs of abuse—pentobarbital example. J Forensic Sci 1995;40:983-989. ElSohly MA, Little TL, Jr, and Stanford DF. Hexadeutero-11-nor-delta 9-tetrahy-drocannabinol-9-carboxylic acid: a superior internal standard for the GC/MS analysis of delta 9-THC acid metabolite in biological specimens. J Anal Toxicol 1992;16:188-191.

Foster DJ, Somogyi AA, and Bochner F. Stereoselective quantification of methadone and its major oxidative metabolite, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine, in human urine using high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 2000;744:165-176. Yanagihara Y, Ohtani M, Kariya S, et al. Stereoselective high-performance liquid chromatographic determination of ketamine and its active metabolite, norketa-mine, in human plasma. J Chromatogr B Biomed Sci Appl 2000;746:227-231. Bogusz M and Erkens M. Influence of biological matrix on chromatographic behavior and detection of selected acidic, neutral, and basic drugs examined by means of a standardized HPLC-DAD system. J Anal Toxicol 1995;19:49-55. Bogusz MJ. Large amounts of drugs may considerably influence the peak areas of their coinjected deuterated analogues measured with APCI-LC-MS. J Anal Toxicol 1997;21:246-247.

Dams R, Huestis MA, Lambert WE, and Murphy CM. Matrix effect in bio-analysis of illicit drugs with LC-MS/MS: influence of ionization type, sample preparation, and biofluid. J Am Soc Mass Spectrom 2003; 14:1290-1294.

199. Muller C, Schafer P, Stortzel M, Vogt S, and Weinmann W. Ion suppression effects in liquid chromatography-electrospray-ionisation transport-region collision induced dissociation mass spectrometry with different serum extraction methods for systematic toxicological analysis with mass spectra libraries. J Chro-matogr B Analyt Technol Biomed Life Sci 2002;773:47-52.

200. Aebi B and Bernhard W. Advances in the use of mass spectral libraries for forensic toxicology. J Anal Toxicol 2002;26:149-156.

201. Gergov M, Weinmann W, Meriluoto J, Uusitalo J, and Ojanpera I. Comparison of product ion spectra obtained by liquid chromatography/triple-quadrupole mass spectrometry for library search. Rapid Commun Mass Spectrom 2004;18: 1039-1046.

202. Kratzsch C, Peters FT, Kraemer T, Weber AA, and Maurer HH. Screening, library-assisted identification and validated quantification of fifteen neuroleptics and three of their metabolites in plasma by liquid chromatography/mass spec-trometry with atmospheric pressure chemical ionization. J Mass Spectrom 2003; 38:283-295.

203. Santos LS, Haddad R, Hoehr NF, Pilli RA, and Eberlin MN. Fast screening of low molecular weight compounds by thin-layer chromatography and "on-spot" MALDI-TOF mass spectrometry. Anal Chem 2004;76:2144-2147.

204. Armbruster DA, Tillman MD, and Hubbs LM. Limit of detection (LQD)/limit of quantitation (LOQ): comparison of the empirical and the statistical methods exemplified with GC-MS assays of abused drugs. Clin Chem 1994;40:1233-1238.

205. Baselt RC. Commentary on Wu AHB, Hill DW, Crouch D, Hodnett CN, McCurdy HH. Minimal standards for the performance and interpretation of toxicology tests in legal proceedings. J Forensic Sci 2000;45:507.

206. Underwood PJ, Kananen GE, and Armitage EK. A practical approach to determination of laboratory GC-MS limits of detection. J Anal Toxicol 1997;21:12-16.

207. Wu AH. Mechanism of interferences for gas chromatography/mass spectrometry analysis of urine for drugs of abuse. Ann Clin Lab Sci 1995;25:319-329.

208. Wu AH, Hill DW, Crouch D, Hodnett CN, and McCurdy HH. Minimal standards for the performance and interpretation of toxicology tests in legal proceedings. J Forensic Sci 1999;44:516-522.

209. ElSohly MA. Practical challenges to positive drug tests for marijuana. Clin Chem 2003;49:1037-1038.

210. ElSohly MA, and Jones AB. Drug testing in the workplace: could a positive test for one of the mandated drugs be for reasons other than illicit use of the drug? J Anal Toxicol 1995;19:450-458.

211. Kapur BM. Drug-testing methods and clinical interpretations of test results. Bull Narc 1993;45:115-154.

212. Kidwell DA. Discussion: caveats in testing for drugs of abuse. NIDA Res Monogr 1992;117:98-120.

An Addict's Guide To Freedom

An Addict's Guide To Freedom

Get All The Support And Guidance You Need To Be A Success At Understanding And Getting Rid Of Addictions. This Book Is One Of The Most Valuable Resources In The World When It Comes To New Ways To Understand Addicts And Get Rid Of Addictions.

Get My Free Ebook


Post a comment